Loratadine

Administration

• Type: H1 antagonists (second generation)
• Dosage Forms: Tablets (chewable or orally disintegrating tablets [ODTs]), liquid-filled capsules, or a syrup (1 mg/mL solution)
• Routes of Administration: Oral
• Common Trade Names: Claritin

Adult Dosing

Allergic rhinitis

• 10 mg PO once daily, OR
• 5 mg twice daily
• Do not exceed 10 mg in 24 hours

Urticaria

• 10 mg PO once daily
  • Some patients may benefit from higher doses. Clinicians should weigh the risks against the benefits.

Pediatric Dosing

Allergic rhinitis

• Children aged ≥6 years old
  • 10 mg PO once daily, OR
• Children aged 2 to 5
  • 5 mg PO once daily
  • Do not exceed 10 mg in 24 hours
  • The ODT formulation is not recommended for younger children.

Urticaria

• Children aged ≥6 years old
  • 10 mg PO once daily
    • Some patients may benefit from higher doses. Clinicians should weigh the risks against the benefits.

Special Populations

Pregnancy Rating

• Should be safe for use during pregnancy; the risk of harm to the fetus is not expected based on limited human data;

Lactation risk

• Caution is advised; nursing mothers may use the medication for a short time. Both loratadine and its active metabolite pass readily into breast milk. There is no known risk of infant harm based on the drug's properties and the currently limited human data.

Renal Dosing

• Adult:
• Pediatric:

Hepatic Dosing

• Adult:
• Pediatric:

Contraindications

• Allergy to class/drug

Pharmacology

• Half-life:
• Metabolism:
• Excretion: